|1.||Monge, Luis: 7 articles (02/2008 - 12/2002)|
|2.||Diéguez, Godofredo: 7 articles (02/2008 - 12/2002)|
|3.||Fernández, Nuria: 7 articles (02/2008 - 12/2002)|
|4.||García-Villalón, Angel Luis: 4 articles (02/2008 - 05/2004)|
|5.||Climent, Belén: 3 articles (01/2006 - 12/2002)|
|6.||Gonzalez-Alvarez, Rafael: 2 articles (09/2015 - 04/2012)|
|7.||Espinoza-Gómez, Francisco: 2 articles (09/2015 - 04/2012)|
|8.||Martinez-Martinez, Rafael: 2 articles (09/2015 - 04/2012)|
|9.||Valdez-Velazquez, Laura L: 2 articles (09/2015 - 04/2012)|
|10.||Guzman-Esquivel, Jose: 2 articles (09/2015 - 04/2012)|
01/01/1983 - "Analysis of variance of the data from those patients who completed 12 weeks in the trial showed that in the sodium meclofenamate group there was a significant improvement in articular index, left grip strength, pain severity and patients' global assessment over the course of the study. "
02/01/1993 - "Moreover the analgesic effect was significantly greater in the meclofenamic acid group with respect to the naproxene group, after 15 minutes for pain at rest (P < 0.05) and after 30 minutes for pain after movement (P < 0.02). "
05/01/1985 - "When compared with the placebo, meclofenamate sodium at either dose level produced a significantly greater reduction in pain intensity, greater pain relief, fewer withdrawals for inefficacy, greater percentage of patients who considered their medication effective, and greater percentage of patients considered by the investigator to have received drug-attributable benefits. "
05/01/1985 - "Meclofenamate sodium appears to be a safe and effective analgesic for the control of pain."
02/01/1993 - "Similarly, after 4 and 8 days, both types of pain improved to a larger extent in the meclofenamic acid group with respect to the naproxene group (P < 0.05 after four days and P < 0.01 after eight days). "
01/01/1983 - "Meclofenamate sodium is a safe, effective agent for the treatment of rheumatoid arthritis."
01/01/1981 - "A single-blind crossover trial was carried out in 21 patients with active rheumatoid arthritis to assess the effectiveness and tolerance of sodium meclofenamate (300 mg per day) compared with placebo. "
01/01/1988 - "Plasma and synovial fluid meclofenamic acid concentrations in patients with rheumatoid arthritis of the knee."
01/01/1983 - "Double-blind multicenter studies with meclofenamate sodium in the treatment of rheumatoid arthritis in the United States and Canada."
01/01/1981 - "Sodium meclofenamate showed good control of disease activity and was generally well tolerated in the treatment of rheumatoid arthritis."
10/01/1987 - "A double-blind, placebo-controlled crossover trial was undertaken to determine the efficacy of meclofenamate sodium in the treatment of menorrhagia. "
10/01/1987 - "Treatment of menorrhagia with meclofenamate sodium."
01/01/1991 - "A brief review of meclofenamic acid use for primary dysmenorrhea, menorrhagia, and episiotomy pain is followed by an original study of this compound in postsurgical pain and stress. "
01/01/1991 - "Meclofenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) approved for use in arthritis (osteo and rheumatoid), analgesia (mild to moderate pain), dysmenorrhea, and heavy menstrual blood loss (menorrhagia). "
|4.||Prostatic Neoplasms (Prostate Cancer)
04/01/2012 - "In vivo trials were divided into two phases; meclofenamic acid toxicity was initially determined at different doses (0, 5, 10 and 20 mg/kg/day/25 days) in BALB/c mice, after which a trial using non-toxic doses was carried out to evaluate the antitumor efficacy of the drug in a PC3/nude-mouse model of human androgen-independent prostate cancer. "
09/01/2015 - "Further studies are needed to evaluate the molecular changes that cause the beneficial and therapeutic effects of meclofenamic acid in androgen-independent prostate cancer. "
09/01/2015 - "The objective of the present work was to analyze the histological changes caused by meclofenamic acid in androgen-independent prostate cancer. "
04/01/2012 - "Meclofenamic acid was shown to be a potential antineoplastic agent for both androgen-dependent and androgen-independent prostate cancer."
04/01/2012 - "Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation."
|5.||Nephrotic Syndrome (Syndrome, Nephrotic)
03/01/1984 - "This report suggests that administration of meclofenamate might be beneficial in some patients with corticosteroid-resistant nephrotic syndrome and FSGS. "
04/01/1991 - "Meclofenamate treatment of posttransplant nephrotic syndrome."
09/01/1985 - "Treatment of severe nephrotic syndrome with meclofenamate: an uncontrolled pilot study."
03/01/1984 - "Meclofenamate and the nephrotic syndrome: the use of the right drug in the right patient by the right physician."
03/01/1984 - "Recurrence of the nephrotic syndrome in the second renal allograft was successfully controlled by the administration of meclofenamate, and the renal function has remained stable for 2 1/2 years. "
|1.||Meclofenamic Acid (Meclofenamate)
|3.||Aspirin (Acetylsalicylic Acid)
|7.||Codeine (Codeine Phosphate)
|8.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|10.||Leukotriene Receptors (Leukotriene Receptor)
|3.||Oral Surgery (Maxillofacial Surgery)